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INTRODUCTION 
 
 Pancreatic cancer is the fourth main cancer in the 
western world. Currently the only chemotherapy available 
clinically is gemcitabine. However, gemcitabine treatment 
only proves effective in 23.8% of patients [2].  
 Nano-structures (<120 nm) are capable of entering the 
highly permeable blood capillaries which supply the rapidly 
growing tumours. Once inside the capillaries they 
accumulate and are retained in the tumour as a result of the 
poor lymphatic drainage. This allows for a deeper tissue 
penetration which is otherwise difficult to achieve. 
 In this work novel prodrugs of gemcitabine have been 
developed which are capable of linkage on to hybrid gold-
iron oxide nanoparticles (HNPs) in order to achieve deeper 
tissue penetration and increase drug efficacy. The linker 
used in this work is proposed to break down upon enzymatic 
hydrolysis in vivo, hence liberating the free drug. 
 
MATERIALS AND METHODS 
 
 Gemcitabine was reacted with lipoic acid using 
established procedures to deliver prodrugs. These 
compounds were characterised using a combination of 
spectroscopic and spectrometric techniques including 19F 
nuclear magnetic resonance spectroscopy (NMR). HNPs 
were synthesised and characterised using transmission 
electron microscopy (TEM), photon correlation 
spectroscopy (PCS) and inductively coupled plasma – 
optical emission spectroscopy (ICP-OES). 
 Attachment of prodrugs on to hybrid nanoparticulate 
surface was quantified using reverse phase high 
performance liquid chromatography (HPLC). In vitro drug 
release studies were carried out at varied pH: 7.8, 5.4 & 3.6 
and quantified by HPLC. In vitro cytotoxicity of the novel 
formulations was carried out on BxPC-3 cells and compared 
with the free drug using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Drug 
internalisation was quantified per cell by HPLC.  
  
RESULTS AND DISCUSSION 
 
 Novel prodrugs of gemcitabine were isolated which are 
substituted at the amine in the 4 position of the pyrimidine 
nucleus and at the 3’ and 5’ hydroxyl groups of the 2,2’-
difluororibose moiety. The structure of these compounds 
was confirmed using multinuclear NMR spectroscopy.  
 HNPs were synthesised successfully in the magnitude of 
70 nm (Fig. 1.) The dark appearance and lack of 2 nm gold 
seeds on the TEM indicate successful coating had occurred. 
Prodrug attachment to HNP was successful with as much as 
5 mg mL-1 being detected. Drug release studies indicated 
that the formulation was stable over the range of pH’s 
tested.  
 
 
 
 
Fig. 1. Transmission electron microscopy of HNP-gemcitabine prodrug 
formulation showing particle size and morphology. 
 
 In vitro cytotoxicity assays showed that the novel 
formulation possessed a lower IC50 value compared with 
free drug (5-fold). Additionally, the intracellular 
concentration of drug was lower than for the formulation. It 
is postulated that the formulation is entering more rapidly 
using a different entry mechanism to the free drug resulting 
in raised intracellular concentrations and cytotoxic effect. 
 
CONCLUSIONS 
 
Further work is on-going to investigate the potential of the 
prodrug-nanoparticulate constructs in vivo for pancreatic 
cancer therapy. 
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